A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders

作者：Yamakawa Noriyuki; Fujimoto Masakazu; Kawabata Daisuke^*; Terao Chikashi; Nishikori Momoko; Nakashima Ran; Imura Yoshitaka; Yukawa Naoichiro; Yoshifuji Hajime; Ohmura Koichiro; Fujii Takao; Kitano Toshiyuki; Kondo Tadakazu; Yurugi Kimiko; Miura Yasuo; Maekawa Taira; Saji Hiroh; Takaori Kondo Akifumi; Matsuda Fumihiko; Haga Hironori; Mimori Tsuneyo

来源：Journal of Rheumatology, 2014, 41(2): 293-299.

DOI：10.3899/jrheum.130270

• RHEUMATIC DISEASES
• RHEUMATOID ARTHRITIS SKIN MANIFESTATIONS
• HLA ANTIGENS
• HEMATOPOIETIC SYSTEM

Objective. Methotrexate-associated lymphoproliferative disorders (MTX-LPD) often regress spontaneously during MTX withdrawal, but the prognostic factors remain unclear. The aim of our study was to clarify the clinical, histological, and genetic factors that predict outcomes in patients with MTX-LPD.
Methods. Patients with MTX-LPD diagnosed between 2000 and 2012 were analyzed retrospectively regarding their clinical course, site of biopsy, histological typing, Epstein-Barr virus (EBV) in situ hybridization and immunostaining, and HLA type.
Results. Twenty-one patients, including 20 with rheumatoid arthritis (RA) and I with polymyositis, were analyzed. The mean dose of MTX was 6.1 mg/week and the mean duration of treatment was 71.1 months. Clinically, 5 patients were diagnosed with EBV-positive mucocutaneous ulcer (EBVMCU) and had polymorphic histological findings. The proportion of those patients successfully treated solely by withdrawal of MIX was significantly greater than that of those without EBVMCU (75% vs 7.7%, p = 0.015). The HLA-B15:11 haplotypc was more frequent in patients with EBV+ RA with MTX-LPD than in healthy Japanese controls (p = 0.0079, Bonferroni's method). EBV latency classification and HLA typing were not associated with the prognosis of MTX-LPD in our cohort.
Conclusion. Our data demonstrate that patients in the EBVMCU, a specific clinical subgroup of MTX-LPD, had a better clinical outcome when MIX was withdrawn than did other patients with MTX-LPD.

• 出版日期2014-2